Abeona Therapeutics Inc. (ABEO) Stock Price & Analysis

Abeona Therapeutics Inc. (ABEO) rose 1.30% to USD 5.45 as of June 10, 2026 at 04:34 UTC, according to Nexqual real-time market data.

ABEO last closed at USD 5.38; the session ranged USD 5.24–5.48 on volume of 1,159,497 shares. Market capitalization is $310.62M, with a 52-week range of USD 4–7.54 (NCM). Source: Nexqual, June 10, 2026 at 04:34 UTC.

Key Statistics (as of June 10, 2026 at 04:34 UTC)

Technical Analysis (ABEO)

Nexqual's technical model rates ABEO "NEUTRAL" based on 2 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 04:34 UTC.

Analyst Ratings (ABEO)

Wall Street analysts rate ABEO "Strong Buy" based on 7 analysts, with a mean price target of USD 19.71 (range USD 14–28), per Nexqual as of June 10, 2026 at 04:34 UTC.

Earnings (ABEO)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 04:34 UTC.

Financials & Fundamentals (ABEO)

Source: Nexqual, June 10, 2026 at 04:34 UTC.

Financial Health Score (ABEO)

Nexqual rates Abeona Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:34 UTC.

Ownership (ABEO)

Source: Nexqual, June 10, 2026 at 04:34 UTC.

Leadership (ABEO)

Abeona Therapeutics Inc. is led by Vishwas Seshadri (age 49), President, CEO & Director, per Nexqual as of June 10, 2026 at 04:34 UTC.

Major Backers & Investors (ABEO)

Notable institutional backers of Abeona Therapeutics Inc. include Nantahala Capital Management, LLC, AIGH Capital Management LLC, Cable Car Capital, LP, according to Nexqual as of June 10, 2026 at 04:34 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 04:34 UTC.

From Abeona Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)

Key Strengths & Strategy (as disclosed to the SEC)

• Biologic Products Development Process   In the United States, the FDA regulates biologic products including gene therapy products under the Federal Food, Drug, and Cosmetic Act ("FDCA"), the Public Health Service Act ("PHSA"), and regulations implementing these laws.
• We also rely on trade secrets and know-how relating to our proprietary technology platforms, continuing technological innovation, and in-licensing opportunities to develop, strengthen and maintain our position in the field of cell and gene therapy.
• Clinical trials must be conducted and monitored in accordance with the FDA's regulations comprising the GCP requirements, including the requirement that all research subjects provide informed consent.   Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted.

Partnerships

• We believe AIM™ vectors also have the potential for redosing subjects who previously received certain AAV gene therapy or subjects who have pre-existing antibodies to naturally occurring AAV serotypes.       In July 2024, we entered into a non-exclusive agreement with Beacon Therapeutics ("Beacon") under which Beacon will evaluate Abeona's patented AAV204 capsid for the development and commercialization of potential gene therapies for select ophthalmology indications.
• In partnership with academic institutions, our own scientific research teams have identified capsids within the AIM™ capsid library showing strong potential to successfully target and reach the central nervous system (including the retina) as well, lung, muscle, liver, and other tissues.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:34 UTC. This page is informational and not investment advice.